A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Inclusion Criteria: * Men and women, age ≥18 and ≤75 years * Pathologically confirmed DLBCL, sufficient diagnostic material should be available to forward to a central laboratory for gene expression profiling and pathology review. * No prior treatment for DLBCL * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * International Prognostic Index (IPI) score of 1 to 5 * Disease Stage II to IV by the Ann Arbor Classification * Adequate organ and marrow function * Agreement to use highly effective forms of contraception during the study and 12 months after the last dose of rituximab Exclusion Criteria: * Evidence of severe or uncontrolled systemic diseases * Known history of a bleeding diathesis (i.e., haemophilia, von Willebrand disease) * History of stroke or intracranial haemorrhage in preceding 6 months. * Known CNS lymphoma or leptomeningeal disease * Known primary mediastinal lymphoma * Known High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements * Prior history of indolent lymphoma or CLL * History of or ongoing confirmed PML * Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification * Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small …